Partners Collaboration opportunities Trained immunity Two studies show potential of trained immunity for the treatment of cancer
29 October 2020

Our immune system consists of two parts; the innate and the acquired immune system. It has long been thought that the acquired part can learn to recognize the pathogens with which it comes into contact, and that the innate part cannot. But in recent years it has become clear that the innate immune system does have a memory and can therefore be 'trained'. This training means that a vaccination, such as the BCG vaccine, can prepare the immune system for, and arm it against, a disease - also of very different pathogens as those with which it has been trained. The pioneering work of Mihai Netea, theme Infectious diseases and global health, among others, focuses on this. 

In two publications published this month in the scientific journal Cell, this trained immunity has been investigated for its potential for cancer treatments. 

Transplantation of trained immunity

In the first study, in mice, Mihai Netea and colleagues at the University of Dresden were able to move trained immune effects from one individual to another by transplanting immune cells. To do so, they first trained the immune system of the donor animals by injecting a substance from fungi known to stimulate the innate immune system. This substance, β-glucan, changes the production of these cells, granulocytes, in the bone marrow in such a way that these cells are more aggressive against tumors. The mice that were subsequently administered these granulocytes also proved more resistant to tumor growth. 
Even after transplanting bone marrow, the tissue that produces granulocytes, this effect remained visible. The study thus shows that the granulocytes can play a key role in the anti-tumor defense of the trained immune system.

Publication:Innate immune training of granulopoiesis promotes 1 anti-tumor activity.

Trained immunity by a designed molecule

In the second study, a large project in which Leo Joosten, theme Tumours of the digestive tract, and Raphael Duivenvoorden, theme Renal disorders, were also involved, it was shown that the trained immunity can be caused by a 'nanobiologic', a designed molecule. The nanobiologic from this study (called MTP10-HDL) was developed by Willem Mulder and colleagues from TU Eindhoven and Mount Sinai Medical School in New York. 
Before the researchers arrived at MTP10-HDL, an extensive screening of all kinds of possible candidates was carried out. This specific molecule appeared to have an inhibitory effect on tumor growth in a mouse model. Subsequently, more in-depth research showed that here, too, the innate immune system was trained by a change in the bone marrow, stimulated by the nanobiologic. The result was that the immune system was able to penetrate more easily into the immediate vicinity of the tumor, which has an inhibiting effect on tumor growth, but may also make other treatments more effective as a kind of catalyst. 

Publication: Trained immunity-promoting nanobiologics suppress tumor growth and potentiate checkpoint blockade immunotherapy

Mihai Netea: "These studies show that stimulating trained immunity can have an important anti-cancer effect. In combination with current immunotherapy with 'checkpoint inhibitors', boosting trained immunity has the potential to significantly improve cancer treatment".

Related news items

Rubicon grants awarded to three RIMLS researchers

19 April 2022

Three researchers have received Rubicon funding from NWO/ZonMw. This will enable Elke Muntjewerff, Laura de Vries and Laurens van de Wiel to do research at a foreign research institute for the next two years.

read more

Poster prize for Valerie Betting

12 April 2022

At the recent EMBO Workshop PIWI proteins and piRNAs, Valerie Betting, theme Infectious Diseases & Global Health, won a poster prize for her poster Elucidating the role of Yb in PIWI4/tapiR-mediated gene silencing.

read more

Neolithic made us taller and more intelligent, but more prone to heart disease How modern European populations have evolved over the past 50,000 years

6 April 2022

After the Neolithic, European populations showed an increase in height and intelligence, reduced skin pigmentation and increased risk of cardiovascular disease due to genetic changes that lowered concentrations of 'good' HDL cholesterol.

read more

Immunogenetic studies in diverse populations are essential Clear immunological differences between populations in Europe and Africa

15 February 2022

Genetic factors that partly determine host defenses sometimes differ significantly between people and populations. This is shown in a publication in the American Journal of Human Genetics by researchers from the Netherlands, Tanzania and India.

read more

Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection

17 February 2021

In a review in Cell Mihai Netea, Frank van de Veerdonk, Reinout van Crevel and Jorge Dominguez Andres propose that induction of trained immunity by whole-microorganism vaccines may represent an important tool for reducing susceptibility to and severity of SARS-CoV-2.

read more